BioCentury
ARTICLE | Clinical News

Abraxane nab-paclitaxel: Phase III started

May 5, 2014 7:00 AM UTC

Celgene disclosed in its 1Q14 earning that it began the open-label, U.S. Phase III APACT (PANC-003) trial to compare 125 mg/m 2 IV Abraxane plus gemcitabine on days 1, 8 and 15 of a 28-day cycle for u...